SCHEMBL12430630

SCHEMBL12430630

c1ccc2c(Nc3cc(C4CC4)[nH]n3)nc(Oc3ccc4c(c3)CCCC4)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.54
SRC P12931 4/20 0.53
GSK3B P49841 4/20 0.53
AURKA O14965 1/20 0.53
ULK1 O75385 4/20 0.52
PAK4 O96013 2/20 0.52
PAK1 Q13153 2/20 0.52
CCNA2 P20248 2/20 0.51
CDK2 P24941 2/20 0.51
NTRK3 Q16288 1/20 0.49
NTRK2 Q16620 1/20 0.49
PDK1 Q15118 1/20 0.47
ULK2 Q8IYT8 1/20 0.47
AURKB Q96GD4 1/20 0.46
IGF1R P08069 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430620 0.88 SRC (0.58) NTRK1SRCGSK3BAURKAULK1
SCHEMBL2206539 0.83 SRC (0.44) NTRK1SRCGSK3BAURKAULK1
SCHEMBL12430628 0.83 SRC (0.63) NTRK1SRCGSK3BAURKAULK1
SCHEMBL14423410 0.81 PAK4 (0.52) NTRK1SRCGSK3BAURKAULK1
SCHEMBL12430670 0.79 ULK1 (0.72) NTRK1SRCGSK3BAURKAULK1
SCHEMBL7156974 0.76 AURKA (0.36) SRCGSK3BAURKA
SCHEMBL31471756 0.74 ULK1 (0.71) NTRK1SRCGSK3BULK1PAK4
SCHEMBL29618398 0.74 ULK1 (0.65) NTRK1SRCGSK3BULK1PAK4
SCHEMBL786513 0.74 ULK1 (0.65) NTRK1SRCGSK3BULK1PAK4
SCHEMBL3998184 0.73 SRC (0.80) NTRK1SRCGSK3BAURKAULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA NTRK1 2111/4885SRC 298/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.